Cullinan Therapeutics, Inc. (CGEM) Stock Price & Analysis
Cullinan Therapeutics, Inc. (CGEM) closed at USD 14.92 on Thursday, October 22, 2026, up 0.20% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 14.89; the Oct 22, 2026 session ranged USD 14.64–15.32 on volume of 392,650 shares. Market capitalization is $916.95M, with a 52-week range of USD 6.73–23.19 (NMS). Source: Nexqual, retrieved October 23, 2026 at 10:12 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CGEM.md
Key facts (CGEM)
- Insider open-market sales, last ~7 months: 4 Form 4 filings, $1.0M; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 4 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 1.92 on a 1–5 scale) (12 analysts), mean target USD 34.5 (range 27–42).
- Total return with dividends: 1Y +93.0% vs S&P 500 +14.9%; 5Y -32.8% vs S&P 500 +80.3%.
- Next earnings: 2026-11-14, EPS estimate USD -0.84, revenue estimate $0K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CGEM)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $18.9M | $0K | — | — | — | — |
| Operating income | -$68.0M | $145M | -$191M | -$197M | -$242M | -$222M |
| Net income | -$65.6M | $111M | -$153M | -$167M | -$220M | -$205M |
| EPS (diluted) | -$1.52 | $2.38 | -$3.69 | — | — | — |
| Free cash flow | -$43.4M | -$128M | -$134M | -$145M | -$176M | — |
| Operating margin | -358.7% | — | — | — | — | — |
| Net margin | -346.1% | — | — | — | — | — |
| Revenue growth | — | -100.0% | — | — | — | — |
| Cash + short-term investments | $290M | $467M | $467M | $399M | $378M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (CGEM)
P/B 2.9x · Earnings yield -22.32%
Insider sales (SEC Form 4, open-market, last ~7 months) (CGEM)
4 of 4 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-08 | Michaelson Jennifer | Chief Scientific Officer | 8,000 | $173K | 4.8% | Yes | Routine (sold in Dec each year 2023–2025; this trade is outside those months) |
| 2026-08-13 | Michaelson Jennifer | Chief Scientific Officer | 30,000 | $608K | 15.6% | Yes | Routine (sold in Dec each year 2023–2025; this trade is outside those months) |
| 2026-07-06 | Michaelson Jennifer | Chief Scientific Officer | 8,000 | $143K | 4.7% | Yes | Routine (sold in Dec each year 2023–2025; this trade is outside those months) |
| 2026-05-05 | Michaelson Jennifer | Chief Scientific Officer | 8,000 | $117K | 4.6% | Yes | Routine (sold in Dec each year 2023–2025; this trade is outside those months) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (CGEM)
Consensus Buy (mean 1.92 on a 1–5 scale), 12 analysts; mean target USD 34.5 (low 27, high 42).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-19 | BTIG | Reiterated | Buy | $40 |
| 2026-10-02 | HC Wainwright & Co. | Reiterated | Buy | $35 |
| 2026-09-25 | HC Wainwright & Co. | Target raised | Buy | $30 → $35 |
| 2026-09-25 | BTIG | Reiterated | Buy | $40 |
| 2026-09-14 | BTIG | Target raised | Buy | $39 → $40 |
| 2026-08-17 | HC Wainwright & Co. | Reiterated | Buy | $30 |
| 2026-08-13 | Wedbush | Target raised | Outperform | $39 → $42 |
| 2026-07-29 | BTIG | Target raised | Buy | $38 → $39 |
Total return (dividends reinvested) (CGEM)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +93.0% | -32.8% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +93.5% | -7.6% |
| Volatility (annualized) | 78.3% | 62.8% |
| Max drawdown | -43.7% (Aug 2026→Oct 2026) | -79.2% (Apr 2024→Sep 2025) |
CGEM analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.84 | $-0.86 | -2.6% | $0 | 9 |
| Next quarter (ends Dec 2026) | $-0.70 | $-0.50 | +40.1% | $11.6M | 9 |
| Current fiscal year (ends Dec 2026) | $-3.13 | $-3.00 | +4.3% | $13.9M | 9 |
| Next fiscal year (ends Dec 2027) | $-2.52 | $-2.53 | -0.4% | $52.8M | 9 |
Key Statistics (as of October 23, 2026 at 10:12 UTC)
| Price | USD 14.92 |
|---|---|
| Change | ▲ 0.20% (up) |
| Previous Close | USD 14.89 |
| Open | USD 14.82 |
| Day Range | USD 14.64 – 15.32 |
| 52-Week Range | USD 6.73 – 23.19 |
| Volume | 392,650 shares |
| Market Cap | $916.95M |
| Exchange | NMS |
Technical Analysis (CGEM)
Nexqual's technical model rates CGEM "SELL" based on 1 bullish and 4 bearish signals across 127 daily candles, as of October 23, 2026 at 10:12 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 39.82 (neutral) |
| vs SMA50 | Below (USD 18.62) |
| MACD | -1.13 (negative) |
Analyst Ratings (CGEM)
Wall Street analysts rate CGEM "Buy" based on 12 analysts, with a mean price target of USD 34.5 (range USD 27–42), per Nexqual as of October 23, 2026 at 10:12 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 34.5 |
| High Target | USD 42 |
| Low Target | USD 27 |
| Buy / Hold / Sell | 12 / 0 / 0 |
Earnings (CGEM)
| Next Earnings Date | 2026-11-14 |
|---|---|
| EPS Estimate | USD -0.84 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.81 vs est -0.85 ▲ beat |
| 2026-03-31 | USD -0.75 vs est -0.84 ▲ beat |
| 2025-12-31 | USD -0.77 vs est -0.84 ▲ beat |
| 2025-09-30 | USD -0.77 vs est -0.89 ▲ beat |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Financials & Fundamentals (CGEM)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -50.30% |
| Debt / Equity | 0.01 |
| Current Ratio | 8.42 |
| Total Cash | $334.54M |
| Total Debt | $2.07M |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Financial Health Score (CGEM)
Nexqual rates Cullinan Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:12 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $335M cash vs $2M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$176M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -50%, ROA -31.4% |
Ownership (CGEM)
| Insider Ownership | +0.43% |
|---|---|
| Institutional Ownership | +112.54% |
| Shares Outstanding | 61.46M |
| Float | 48.09M |
| Short % of Float | +16.52% |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Leadership (CGEM)
Cullinan Therapeutics, Inc. is led by Nadim Ahmed M.S., President, CEO & Director, per Nexqual as of October 23, 2026 at 10:12 UTC.
| President, CEO & Director | Nadim Ahmed M.S. |
|---|---|
| Chief Financial Officer | Mary Kay Fenton |
| Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board | Patrick A. Baeuerle |
| Chief Scientific Officer | Jennifer Michaelson |
| Senior Vice President of Corporate Affairs | Rose Weldon |
Major Backers & Investors (CGEM)
Notable institutional backers of Cullinan Therapeutics, Inc. include MPM Bioimpact LLC, Lynx1 Capital Management Lp, BVF Inc., according to Nexqual as of October 23, 2026 at 10:12 UTC.
Active Investors
| Investor | Stake |
|---|---|
| MPM Bioimpact LLC | 15.12% |
| Lynx1 Capital Management Lp | 13.93% |
| BVF Inc. | 8.94% |
| Price (T.Rowe) Associates Inc | 5.95% |
| Kynam Capital Management, LP | 4.84% |
| RTW Investments LP | 3.67% |
| T. Rowe Price | 3.36% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.13% |
| State Street | 5.7% |
| Vanguard Group | 4.06% |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 90.9 | ▲ 2.57% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| ABVX | Abivax SA | USD 90.23 | ▼ 3.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:12 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt